Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the United States Securities and Exchange Commission ("SEC").
The addition of the Clayton site in 2011 marked a new milestone for Grifols, turning the company into a top-three plasma industry leader and setting the stage for sustained business growth The flagship Grifols campus is a touchstone of Grifols’ leadership in plasma therapeutics, producing about 40% of the company’s total medicinal output globally and helping enhance the quality of life of patients all over the worldAn engineering masterwork, the Clayton site is a model for new Grifols plants whi
MADRID (Reuters) -Spanish drug maker Grifols, battling a plunge in its share price this year, plans to add independent directors to its audit and compensation committees to improve its governance, its chairman said in a newspaper interview published on Sunday. Grifols' market value has shed billions of euros since short-sheller Gotham City Research released three reports in early January accusing the company of overstating earnings and understating debt. Grifols has repeatedly denied the claim...
(Bloomberg) -- Grifols SA is seeking to issue a new bond, in what would be its first debt deal since coming under attack from a short seller in January.Most Read from BloombergUS Slams Strikes on Russia Oil Refineries as Risk to Oil MarketsUS Core CPI Tops Forecasts Again, Likely Delaying Fed Rate CutsChinese Cement Maker Halted After 99% Crash in 15 MinutesBond Trader Places Record Futures Bet on Eve of Inflation DataApple’s India iPhone Output Hits $14 Billion in China ShiftThe Barcelona-based
Grifols’ in vitro nucleic acid test detects four types of arboviruses, helping mitigate the risk of transfusion-transmitted infections Arboviruses are a growing emerging threat, with changes in climate and increasing global connectivity making the geographic spread more prevalent CE mark for Grifols’ Procleix ArboPlex Assay reinforces the company’s leadership in transfusion medicine and commitment to ensuring the safety of the world’s blood supply BARCELONA, Spain, April 04, 2024 (GLOBE NEWSWIRE
(Bloomberg) -- Grifols SA shares dropped as investors evaluated a regulatory review of the Spanish bio-science company’s financial reports, which found “relevant deficiencies” but no major accounting mistakes.Most Read from BloombergNY Gears Up to Seize Trump Westchester Assets If Fraud Fine Is UnpaidBaltimore Wants to Sell Hundreds of Vacant Homes for $1 EachWhat Happens If Trump Can’t Post His $454 Million BondChina Scrutinizes PwC Role in $78 Billion Evergrande Fraud CaseYemen’s Houthis Tell
Read about Novo Nordisk, Grifols, Shandong Weigao and more in the latest Market Talks covering the Health Care sector.
Europe's main stock indices were flat on Friday, but notched strong gains over the week that saw record highs from German and French shares, while investors also analysed a U.S. jobs report for clues on the global monetary policy outlook. Technology lost 1.6% after BE Semiconductor slumped 16.1% on a media report that Joint Electron Device Engineering Council lowered certain chip standards which might delay investments into hybrid bonding technology.
Grifols SA (NASDAQ:GRFS) shares are down on Wednesday following the publication of a new report by Gotham City Research questioning the company’s “transparency, integrity and ethical conduct.” Grifols had previously denied Gotham City’s accusations, as per its February SEC filing, saying it had already replied to all of the questions raised in the latter’s reports. Grifols claimed in its public February 20 response that the company had addressed all our questions, yet new information from the Ke
(Bloomberg) -- Grifols SA shares fell the most ever on Thursday after management said the Spanish plasma maker may not generate cash this year, dealing a heavier blow to the stock than last month’s attack by a short seller.Most Read from BloombergFed’s Preferred Inflation Metric Increases by Most in a YearHow Much Wealth You Need to Join the Richest 1% Around the WorldApple to Wind Down Electric Car Effort After Decadelong OdysseyStocks End Month at New Highs After Inflation Data: Markets WrapTr